New FDA approval of Itovebi, a drug that may improve treatment for certain advanced or metastatic breast cancers
https://www.facingourrisk.org/XRAY/Itovebi-for-metastatic-breast-cancer
Full article: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2501796
About one-third of hormone receptor-positive (HR-positive), HER2-negative metastatic breast cancers have a PIK3CA tumor mutation that can increase cancer growth and lead to treatment resistance. A new targeted therapy, Itovebi (inavolisib), improved patient outcomes when combined with standard treatment. This led to the recent FDA approval of the drug. (Posted 7/3/25)
Questions To Ask Your Health Care Provider
- What type of breast cancer do I have? Is my cancer HR-positive? HER2-negative?
- Does my cancer have a PIK3CA tumor mutation?
- Should I consider additional tumor biomarker testing for a PIK3CA mutation?
- What are the treatment options for my breast cancer?
- What are the risks and benefits of taking Itovebi?
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.